| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6958161 | MAYNE PHARMA | Modified release coated drug preparation |
Dec, 2022
(1 year, 4 months ago) | |
| US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(3 years from now) | |
Doryx is owned by Mayne Pharma.
Doryx contains Doxycycline Hyclate.
Doryx has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Doryx are:
- US6958161
Doryx was authorised for market use on 19 December, 2014.
Doryx is available in tablet, delayed release;oral dosage forms.
Doryx can be used as to treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet.
The generics of Doryx are possible to be released after 03 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Apr 11, 2016 |
| New Dosing Schedule(D-136) | Apr 11, 2016 |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 19 December, 2014
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
DORYX family patents
